Jushi Holdings Inc. Announces Applications Submitted for DEA Registration of State-Licensed Medical Cannabis Operations

Article content

BOCA RATON, Fla., May 28, 2026 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, today announced that it has submitted applications to the U.S. Drug Enforcement Administration (“DEA”) seeking registration for certain state-licensed medical marijuana operations under the federal framework established following the rescheduling of medical marijuana to Schedule III under the Controlled Substances Act.

Article content

Article content

“Pursuing DEA registration is an important milestone for Jushi and the medical patients we serve,” said Jim Cacioppo, Chief Executive Officer of Jushi. “We are focused on operating at the highest regulatory standards and believe this process represents a meaningful step toward a more integrated and transparent national framework for medical cannabis.”

Article content

Article content

Article content

In connection with the reclassification of medical marijuana produced by state-licensed operators to Schedule III, the DEA introduced a streamlined registration pathway for qualified state-licensed medical marijuana operators. This process enables applicants to seek federal registration in connection with the manufacture, distribution, and dispensing of Schedule III medical cannabis products, while relying on existing state medical licenses as part of the qualification process. For operators that submit applications within the initial 60-day filing window, registrations may be granted on an expedited basis unless otherwise notified by the DEA.

Article content

Jushi believes this framework reflects growing federal recognition of the strength and oversight of state medical cannabis programs and provides a pathway toward greater alignment between state and federal regulation. The Company’s applications are intended to position Jushi to participate in this evolving regulatory structure while continuing to serve medical patients in accordance with applicable state laws.

Article content

Article content

“This is an important step for the industry and reinforces what we have consistently heard from our patients about their experience with medical cannabis,” added Cacioppo. “We look forward to engaging with regulators as this framework develops and supporting continued progress in research, patient access, and responsible oversight of medical cannabis in the United States.”

Article content

About Jushi Holdings Inc.

Article content

We are a vertically integrated cannabis company led by an industry-leading management team. Jushi is focused on building a multi-state portfolio of branded cannabis assets through opportunistic acquisitions, distressed workouts, and competitive applications. Jushi strives to maximize shareholder value while delivering high-quality products across all levels of the cannabis ecosystem. For more information, visit jushico.com or our social media channels, Instagram, Facebook, X, and LinkedIn.

Article content

Forward-Looking Information and Statements

Article content

This press release may contain “forward-looking statements” and “forward‐looking information” within the meaning of applicable securities laws, including Canadian securities legislation and United States (“U.S.”) securities legislation (collectively, “forward-looking information”) which are based upon the Company’s current internal expectations, estimates, projections, assumptions and beliefs. All information, other than statements of historical facts, included in this release that address activities, events or developments that the Company expects or anticipates will or may occur in the future constitutes forward‐looking information. Forward‐looking information is often identified by the words, “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes, among others, information regarding: anticipated timing and benefits of the Continuance; future business strategy; competitive strengths, goals, expansion and growth of the Company’s business, operations and plans, including new revenue streams; the refinancing or securing other sources of liquidity to meet debt repayment obligations; the integration and benefits of recently acquired businesses or assets; roll out of new operations; the implementation by the Company of certain product lines; the implementation of certain research and development; the application for additional licenses and the grant of licenses that will be or have been applied for; the expansion or construction of certain facilities; the reduction in the number of our employees; the expansion into additional U.S. and international markets; any potential future legalization of adult use and/or medical marijuana under U.S. federal law; expectations of market size and growth in the U.S. and the states in which the Company operates; expectations for other economic, business, regulatory and/or competitive factors related to the Company or the cannabis industry generally; and other events or conditions that may occur in the future.